Helping you get the best from your
Reconval for Multiple Sclerosis
- Multiple Sclerosis therapy with injectable drugs such as beta-Interferon may be accompanied by frequent local side effects (injection site pain, burning, erythema and necrosis),
- Often these skin changes very severe and may limit your dosing frequency and thus resulting in a reduced efficacy of your treatment
- Sometimes your physician may need to stop therapy and change to an alternative less optimal treatment
- Application of Reconval® K1 reduces local skin reactions and may therefore improve your quality of life, treatment tolerability and overall therapeutic outcome

Literature Reconval and beta-Interferon therapy
- Vitamin K cream reduces reactions at theinjection site in patients with relapsing–remitting multiple sclerosis treated with subcutaneous interferon beta – VIKING study
Roberta Lanzillo, Multiple Sclerosis Centre, Department of Neuroscience, Reproductive Science and Odontostomatology, Federico II University of Naples, Via Pansini 5, Napoli, 80131, Italy.
Multiple Sclerosis Journal, 1–2, DOI: 10.1177/1352458514562989
© The Author(s), 2015.
Reprints and permissions:
www.sagepub.co.uk
journalsPermissions.nav - Multiple Sclerosis: Symptoms and side effects management.
Int J MS Care 2006; 8 (Supplement 1). - Bayas A and Rieckmann P. Managing the adverse effects of interferon-beta therapy in multiple sclerosis.
Drug Saf 2000; 22: 149–159.
Advice for the Reconval K1 application
- Apply Reconval K1 Creme propyhlactically before the first injection of beta-Interferon on a skin area ca. 15x15cm around the planned injection site
- Apply Reconval K1 creme twice daily, ideally shortly before the injection and ca. 6h afterwards
- In case there is an existing skin rash and/or painful swellings around previous injection sites please apply Reconval K1 twice daily until symptoms have disappeared